Quick Answer
Sonoma Pharmaceuticals, Inc. reported Cash and Equivalents of $5.37 million for fiscal year 2025.
Sonoma Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $5.37M | +71.8% |
| 2024 | $3.13M | -18.1% |
| 2023 | $3.82M | -48.4% |
| 2022 | $7.40M | +75.3% |
| 2021 | $4.22M | +14.3% |
| 2020 | $3.69M | +0.1% |
| 2019 | $3.69M | -63.4% |
| 2018 | $10.07M | -42.4% |
| 2017 | $17.46M | +133.8% |
| 2016 | $7.47M | +21.7% |
| 2015 | $6.14M | +12.0% |
| 2014 | $5.48M | -30.6% |
| 2013 | $7.90M | +135.8% |
| 2012 | $3.35M | -23.3% |
| 2011 | $4.37M | -30.2% |
| 2010 | $6.26M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $2.56M | -51.1% | -15.6% |
| September 30, 2025 | $3.04M | -25.6% | -15.8% |
| June 30, 2025 | $3.60M | +39.2% | -32.9% |
| March 31, 2025 | $5.37M | +71.8% | +2.6% |
| December 31, 2024 | $5.24M | +117.6% | +28.4% |
| September 30, 2024 | $4.08M | +90.8% | +57.5% |
| June 30, 2024 | $2.59M | -26.9% | -17.2% |
| March 31, 2024 | $3.13M | -18.1% | +30.0% |
- Sonoma Pharmaceuticals, Inc. showed an increase of +71.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2025 period, Sonoma Pharmaceuticals, Inc.’s cash and equivalents has declined by 14.1% (from $6.26 million to $5.37 million).
- The most recent figure is from Sonoma Pharmaceuticals, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 17, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: